| 缩写名/全名 |
CURR NEUROPHARMACOL
Current Neuropharmacology |
||||||||||||||||||||||||||||||||
| ISSN号 | 1570-159X | ||||||||||||||||||||||||||||||||
| 研究方向 | 医学-神经科学 | ||||||||||||||||||||||||||||||||
| 影响因子 | 2015:3.753, 2016:3.365, 2017:4.068, 2018:4.568, 2019:4.668, | ||||||||||||||||||||||||||||||||
| 出版国家 | ENGLAND | ||||||||||||||||||||||||||||||||
| 出版周期 | Quarterly | ||||||||||||||||||||||||||||||||
| 年文章数 | 79 | ||||||||||||||||||||||||||||||||
| 出版年份 | 2003 | ||||||||||||||||||||||||||||||||
| 是否OA | No | ||||||||||||||||||||||||||||||||
| 审稿周期(仅供参考) | >12周，或约稿 |
||||||||||||||||||||||||||||||||
| 录用比例 | 较易 | ||||||||||||||||||||||||||||||||
| 投稿链接 | http://bsp-cms.eurekaselect.com/index.php/CN | ||||||||||||||||||||||||||||||||
| 投稿官网 | http://benthamscience.com/journal/index.php?journalID=cn | ||||||||||||||||||||||||||||||||
| h-index | 58 | ||||||||||||||||||||||||||||||||
| CiteScore |
|
||||||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1570-159X%5BISSN%5D | ||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2018年新版本） |
|
||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年新版本） |
|
| 中国学者近期发表的论文 | |
| 1. | Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms. Author: Hu LY1, Mi WL1, Wu GC1, Wang YQ1, Mao-Ying QL1. Journal: Curr Neuropharmacol. 2019;17(2):184-196. doi: 10.2174/1570159X15666170915143217. PubMed DOI |
| 2. | The Role of CXCR3 in Neurological Diseases. Author: Zhou YQ1,2, Liu DQ1,2, Chen SP1,2, Sun J1,2, Zhou XR3, Xing C4, Ye DW3, Tian YK1,2. Journal: Curr Neuropharmacol. 2019;17(2):142-150. doi: 10.2174/1570159X15666171109161140. PubMed DOI |
| 3. | Targeting Cytokines for Morphine Tolerance: A Narrative Review. Author: Liu DQ1,2, Zhou YQ1,2, Gao F1,2. Journal: Curr Neuropharmacol. 2019;17(4):366-376. doi: 10.2174/1570159X15666171128144441. PubMed DOI |
| 4. | Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. Author: Fan D1,2,3, Liu L4, Wu Z1,3, Cao M3. Journal: Curr Neuropharmacol. 2019;17(6):563-579. doi: 10.2174/1570159X16666180419141613. PubMed DOI |
| 5. | Does Ceruloplasmin Defend Against Neurodegenerative Diseases? Author: Wang B1,2, Wang XP1,3. Journal: Curr Neuropharmacol. 2019;17(6):539-549. doi: 10.2174/1570159X16666180508113025. PubMed DOI |
| 6. | Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease. Author: Dong J, Cui Y, Li S, Le W. Journal: Curr Neuropharmacol. 2016;14(4):339-55. PubMed |
| 7. | Freezing of Gait in Parkinsonism and its Potential Drug Treatment. Author: Zhang LL, Canning SD, Wang XP. Journal: Curr Neuropharmacol. 2016;14(4):302-6. PubMed |
| 8. | Current Drug Managements of Wilson's Disease: From West to East. Author: Li WJ, Chen C, You ZF, Yang RM, Wang XP. Journal: Curr Neuropharmacol. 2016;14(4):322-5. PubMed |
| 9. | Drug Therapy for Behavioral and Psychological Symptoms of Dementia. Author: Wang F, Feng TY, Yang S, Preter M, Zhou JN, Wang XP. Journal: Curr Neuropharmacol. 2016;14(4):307-13. PubMed |
| 10. | AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease. Author: Wang Y, Wang H, Chen HZ. Journal: Curr Neuropharmacol. 2016;14(4):364-75. PubMed |
|
|
